Work

Questionnaire Survey on Enterococcus faecalis-2001 Supplementation in 137 Patients With Oral Diseases at Two Facilities

Year: 2025

Type: article

Abstract: OBJECTIVE: 2001 (EF-2001) in treating oral candidiasis, suggesting its potential to improve oral microbial flora. However, its effectiveness in other oral conditions remains unclear. This study aimed to evaluate the clinical utility of EF-2001 in a broader range of oral diseases. METHODS: A prospective observational questionnaire-based study was conducted on 137 patients who had used granules or paste containing 7.5×10¹¹ EF-2001. Data were collected from November 2020 to March 2021 and from July 2021 to August 2024 at two different facilities. RESULTS: At facility one (n=38), oral diseases included xerostomia (n=10, 26%), glossitis (n=8, 21%), stomatitis (n=7, 18%), oral candidiasis (n=5, 13%), and oral lichen planus (n=5, 13%). Ten patients were receiving cancer treatment or undergoing perioperative oral care. Intestinal symptoms were reported in 34 patients, mainly constipation (n=27, 71%) and diarrhea (n=7, 18%). Improvement in oral symptoms and intestinal symptoms was observed in 25 of 35 respondents (71%) and 18 of 31 (58%), respectively. The most common time-to-symptom improvement was two to four weeks. A significant association was found between improvements in oral and intestinal symptoms. At facility two (n=99), oral diseases included oral lichen planus (OLP) (n=49, 49%), glossodynia (n=12, 12%), oral candidiasis (n=10, 10%), pemphigus vulgaris (n=6, 6%), and Sjögren's syndrome (n=6, 6%). Intestinal symptoms were reported in 67 patients, mainly constipation (n=51, 52%) and diarrhea (n=16, 16%). Improvement in oral symptoms was reported in 64 of 98 respondents (65%), and in intestinal symptoms in 42 of 65 (65%). The most frequent time-to-improvement was two to four weeks for oral symptoms and four to eight weeks for intestinal symptoms. A significant association was again observed between improvements in oral and intestinal symptoms. CONCLUSION: Supplementation with EF-2001 resulted in subjective improvements in both oral and intestinal symptoms across various oral diseases, with a notable association between the two types of symptom improvement.

Source: Cureus

DOI: 10.7759/cureus.91382